0001209191-23-043439.txt : 20230726
0001209191-23-043439.hdr.sgml : 20230726
20230726170418
ACCESSION NUMBER: 0001209191-23-043439
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230724
FILED AS OF DATE: 20230726
DATE AS OF CHANGE: 20230726
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kauffman Michael
CENTRAL INDEX KEY: 0001364719
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38542
FILM NUMBER: 231114325
MAIL ADDRESS:
STREET 1: C/O KARYOPHARM THERAPEUTICS INC.
STREET 2: 85 WELLS AVENUE, SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kezar Life Sciences, Inc.
CENTRAL INDEX KEY: 0001645666
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473366145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-822-5600
MAIL ADDRESS:
STREET 1: 4000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-07-24
0
0001645666
Kezar Life Sciences, Inc.
KZR
0001364719
Kauffman Michael
C/O KEZAR LIFE SCIENCES, INC.
4000 SHORELINE COURT, SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
0
Stock Option (Right to Buy)
7.63
2023-07-24
4
D
0
8896
D
2029-06-24
Common Stock
8896
0
D
Stock Option (Right to Buy)
2.28
2023-07-24
4
A
0
8896
A
2029-06-24
Common Stock
8896
8896
D
Stock Option (Right to Buy)
5.60
2023-07-24
4
D
0
8896
D
2030-06-23
Common Stock
8896
0
D
Stock Option (Right to Buy)
2.28
2023-07-24
4
A
0
8896
A
2030-06-23
Common Stock
8896
8896
D
Stock Option (Right to Buy)
5.59
2023-07-24
4
D
0
26000
D
2031-06-27
Common Stock
26000
0
D
Stock Option (Right to Buy)
2.28
2023-07-24
4
A
0
26000
A
2031-06-27
Common Stock
26000
26000
D
Stock Option (Right to Buy)
4.80
2023-07-24
4
D
0
26000
D
2032-06-15
Common Stock
26000
0
D
Stock Option (Right to Buy)
2.28
2023-07-24
4
A
0
26000
A
2032-06-15
Common Stock
26000
26000
D
Fully vested and exercisable.
On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
/s/ Marc Belsky, Attorney-in-Fact
2023-07-26